BIOVIC B Stock Overview
A biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Biovica International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.75 |
| 52 Week High | SEK 10.36 |
| 52 Week Low | SEK 1.49 |
| Beta | 1.37 |
| 11 Month Change | 14.58% |
| 3 Month Change | 13.17% |
| 1 Year Change | -59.44% |
| 33 Year Change | -94.77% |
| 5 Year Change | -77.73% |
| Change since IPO | -76.99% |
Recent News & Updates
Recent updates
Is Biovica International (STO:BIOVIC B) In A Good Position To Deliver On Growth Plans?
Jul 18
Here's Why We're Watching Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 02Here's Why We're Not Too Worried About Biovica International's (STO:BIOVIC B) Cash Burn Situation
Aug 02Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Feb 17A Look At The Intrinsic Value Of Biovica International AB (publ) (STO:BIOVIC B)
Jan 19Companies Like Biovica International (STO:BIOVIC B) Can Afford To Invest In Growth
Nov 11We Think Biovica International (STO:BIOVIC B) Can Easily Afford To Drive Business Growth
Aug 06We're Not Worried About Biovica International's (STO:BIOVIC B) Cash Burn
Mar 20Who Has Been Buying Biovica International AB (publ) (STO:BIOVIC B) Shares?
Feb 22What Kind Of Shareholders Hold The Majority In Biovica International AB (publ)'s (STO:BIOVIC B) Shares?
Jan 26The Biovica International (STO:BIOVIC B) Share Price Has Soared 349%, Delighting Many Shareholders
Dec 31
Here's Why We're Not At All Concerned With Biovica International's (STO:BIOVIC B) Cash Burn Situation
Dec 05Shareholder Returns
| BIOVIC B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.9% | 1.5% | -1.0% |
| 1Y | -59.4% | 15.5% | 13.3% |
Return vs Industry: BIOVIC B underperformed the Swedish Biotechs industry which returned 15.5% over the past year.
Return vs Market: BIOVIC B underperformed the Swedish Market which returned 13.3% over the past year.
Price Volatility
| BIOVIC B volatility | |
|---|---|
| BIOVIC B Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOVIC B's share price has been volatile over the past 3 months.
Volatility Over Time: BIOVIC B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 37 | Anders Rylander | www.biovica.com |
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation.
Biovica International AB (publ) Fundamentals Summary
| BIOVIC B fundamental statistics | |
|---|---|
| Market cap | SEK 231.15m |
| Earnings (TTM) | -SEK 124.82m |
| Revenue (TTM) | SEK 7.30m |
31.7x
P/S Ratio-1.9x
P/E RatioIs BIOVIC B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIC B income statement (TTM) | |
|---|---|
| Revenue | SEK 7.30m |
| Cost of Revenue | SEK 413.00k |
| Gross Profit | SEK 6.88m |
| Other Expenses | SEK 131.71m |
| Earnings | -SEK 124.82m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 94.34% |
| Net Profit Margin | -1,711.08% |
| Debt/Equity Ratio | 0% |
How did BIOVIC B perform over the long term?
See historical performance and comparison